Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Ida Schjødt"'
Autor:
Dorota Kwasny, Sheida Esmail Tehrani, Catarina Almeida, Ida Schjødt, Maria Dimaki, Winnie E. Svendsen
Publikováno v:
Sensors, Vol 18, Iss 7, p 2214 (2018)
Candidemia and invasive candidiasis is a cause of high mortality and morbidity rates among hospitalized patients worldwide. The occurrence of the infections increases due to the complexity of the patients and overuse of the antifungal therapy. The cu
Externí odkaz:
https://doaj.org/article/700d13f56b3a4b6f8333603df9c8bcfe
Autor:
Lars K. Gjærde, Lasse H. Jakobsen, Caroline Juhl‐Christensen, Gitte Olesen, Irma Petruskevicius, Marianne T. Severinsen, Claus W. Marcher, Kim Theilgaard‐Mönch, Niels S. Andersen, Lone S. Friis, Brian Kornblit, Søren L. Petersen, Ida Schjødt, Henrik Sengeløv
Publikováno v:
Gjærde, L K, Jakobsen, L H, Juhl-Christensen, C, Olesen, G, Petruskevicius, I, Severinsen, M T, Marcher, C W, Theilgaard-Mönch, K, Andersen, N S, Friis, L S, Kornblit, B, Petersen, S L, Schjødt, I & Sengeløv, H 2023, ' Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020 : A Danish population-based cohort study ', British Journal of Haematology, vol. 200, no. 4, pp. e40-e43 . https://doi.org/10.1111/bjh.18511
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6f3268b6fe42af2eb982920680f7216
https://vbn.aau.dk/da/publications/e0b8f44c-383d-45e2-85a5-75856f368699
https://vbn.aau.dk/da/publications/e0b8f44c-383d-45e2-85a5-75856f368699
Autor:
Frederikke Schierbeck, Jann Mortensen, Niels S. Andersen, Lone S. Friis, Brian Kornblit, Søren L. Petersen, Ida Schjødt, Henrik Sengeløv
Publikováno v:
Schierbeck, F, Mortensen, J, Andersen, N S, Friis, L S, Kornblit, B, Petersen, S L, Schjødt, I & Sengeløv, H 2023, ' Pulmonary function is a strong predictor of 2-year overall survival and non-relapse mortality after allogenic hematopoietic cell transplantation ', European Journal of Haematology, vol. 110, no. 1, pp. 50-59 . https://doi.org/10.1111/ejh.13869
Objectives: The purpose of the study was to assess the validity of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and of pulmonary comorbidity prior to HCT in terms of predicting non-relapse mortality (NRM) and overall sur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02132b702347f1e30f6e3ed2b4ddd5cf
https://curis.ku.dk/ws/files/328537972/European_J_of_Haematology_2022_Schierbeck_Pulmonary_function_is_a_strong_predictor_of_2_year_overall_survival_and.pdf
https://curis.ku.dk/ws/files/328537972/European_J_of_Haematology_2022_Schierbeck_Pulmonary_function_is_a_strong_predictor_of_2_year_overall_survival_and.pdf
Autor:
Lars Klingen Gjærde, Sisse Rye Ostrowski, Frederikke Schierbeck, Niels Smedegaard Andersen, Lone Smidstrup Friis, Brian Kornblit, Søren Lykke Petersen, Ida Schjødt, Henrik Sengeløv
Publikováno v:
Gjærde, L K, Ostrowski, S R, Schierbeck, F, Andersen, N S, Friis, L S, Kornblit, B, Petersen, S L, Schjødt, I & Sengeløv, H 2023, ' Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation ', Transplantation and Cellular Therapy, vol. 29, no. 2, pp. 97.e1-97.e6 . https://doi.org/10.1016/j.jtct.2022.11.009
Soluble ST2 is established as a prognostic biomarker of nonrelapse mortality (NRM) when measured early after allogeneic hematopoietic cell transplantation (HCT). However, less is known about the prognostic value of ST2 measured before transplantation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82b4ddb5622a3cdacf368d0755410d2f
https://curis.ku.dk/ws/files/340538996/1_s2.0_S2666636722017730_main.pdf
https://curis.ku.dk/ws/files/340538996/1_s2.0_S2666636722017730_main.pdf
Autor:
Mark-David Levin, Julie Dubois, Rogier Mous, Ellen C Dompeling, Hoa T. T. Tran, Mar Bellido, Christian Bjørn Poulsen, Juha Ranti, Sabina Kersting, Ida Schjødt, Arnon P. Kater, Ann Janssens, Henrik Frederiksen, Clemens Mellink, Johan A. Dobber, Mattias Mattsson, Carsten Utoft Niemann, Lisbeth Enggaard, Gerrit J Veldhuis, Kazem Nasserinejad
Publikováno v:
Blood, 137(8), 1117-1120. AMER SOC HEMATOLOGY
Niemann, C U, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Kater, A P 2021, ' Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia ', Blood, vol. 137, no. 8, pp. 1117-1120 . https://doi.org/10.1182/blood.2020008608
Blood, 137(8), 1117-1120. American Society of Hematology
Niemann, C U, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Kater, A P 2021, ' Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia ', Blood, vol. 137, no. 8, pp. 1117-1120 . https://doi.org/10.1182/blood.2020008608
Niemann, C U, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Kater, A P 2021, ' Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia ', Blood, vol. 137, no. 8, pp. 1117-1120 . https://doi.org/10.1182/blood.2020008608
Blood, 137(8), 1117-1120. American Society of Hematology
Niemann, C U, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Kater, A P 2021, ' Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia ', Blood, vol. 137, no. 8, pp. 1117-1120 . https://doi.org/10.1182/blood.2020008608
ispartof: BLOOD vol:137 issue:8 pages:1117-1120 ispartof: location:United States status: published
Autor:
Arnon P Kater, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J Veldhuis, Rogier Mous, Clemens H M Mellink, Anne-Marie F van der Kevie-Kersemaekers, Johan A Dobber, Christian B Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C Dompeling, Juha Ranti, Christian Brieghel, Mattias Mattsson, Mar Bellido, Hoa T T Tran, Kazem Nasserinejad, Carsten U Niemann
Publikováno v:
The Lancet Oncology, 23(6), 818-828. Lancet Publishing Group
Kater, A P, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, van der Kevie-Kersemaekers, A-M F, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Brieghel, C, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Niemann, C U 2022, ' Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION) : primary analysis of an open-label, randomised, phase 2 trial ', The Lancet Oncology, vol. 23, no. 6, pp. 818-828 . https://doi.org/10.1016/S1470-2045(22)00220-0
Lancet Oncology, 23(6), 818-828. ELSEVIER SCIENCE INC
The Lancet. Oncology, 23(6), 818-828. Lancet Publishing Group
Kater, A P, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, van der Kevie-Kersemaekers, A-M F, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Brieghel, C, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Niemann, C U 2022, ' Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION) : primary analysis of an open-label, randomised, phase 2 trial ', The Lancet Oncology, vol. 23, no. 6, pp. 818-828 . https://doi.org/10.1016/S1470-2045(22)00220-0
Lancet Oncology, 23(6), 818-828. ELSEVIER SCIENCE INC
The Lancet. Oncology, 23(6), 818-828. Lancet Publishing Group
Background Targeted time-limited treatment options are needed for patients with relapsed or refractory chronic lymphocytic leukaemia. The aim of this study was to investigate the efficacy of minimal residual disease (MRD)-guided, time-limited ibrutin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9718c77415d917a2bcc69c56884dfe80
https://research.vumc.nl/en/publications/49812a92-aba6-438b-9c67-b32e46e2a31b
https://research.vumc.nl/en/publications/49812a92-aba6-438b-9c67-b32e46e2a31b
Autor:
Lia Minculescu, Lars Klingen Gjærde, Søren Lykke Petersen, Henrik Sengeløv, Niels Smedegaard Andersen, Ida Schjødt, Lone Smidstrup Friis, Brian Kornblit, Sisse R. Ostrowski
Publikováno v:
European Journal of Haematology. 106:417-424
Objectives Vitamin E has antioxidant and immunomodulatory effects that might influence the development of acute graft-versus-host disease (GvHD). We investigated the association between plasma vitamin E levels and acute GvHD. Methods We studied 115 a
Autor:
Brian Kornblit, Lone Smidstrup Friis, Niels Smedegaard Andersen, Søren Lykke Petersen, Jakob Werner Hansen, Kirsten Grønbæk, Ida Schjødt, Eileen Wedge, Henrik Sengeløv
Publikováno v:
Wedge, E, Sengeløv, H, Hansen, J W, Andersen, N S, Schjødt, I, Petersen, S L, Kornblit, B, Grønbæk, K & Friis, L S 2020, ' Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes ', Biology of Blood and Marrow Transplantation, vol. 26, no. 6, pp. 1091-1098 . https://doi.org/10.1016/j.bbmt.2020.02.010
While allogeneic hematopoietic stem cell transplantation (allo-HCT) currently offers the only curative option for patients with myelodysplastic syndrome (MDS), there is still a high risk of relapse or transplant-related complications. We collected da
Autor:
Lars Klingen Gjærde, Sisse Rye Ostrowski, Niklas Rye Jørgensen, Frederikke Schierbeck, Niels Smedegaard Andersen, Lone Smidstrup Friis, Brian Kornblit, Søren Lykke Petersen, Ida Schjødt, Henrik Sengeløv
Publikováno v:
Gjærde, L K, Ostrowski, S R, Jørgensen, N R, Schierbeck, F, Andersen, N S, Friis, L S, Kornblit, B, Petersen, S L, Schjødt, I & Sengeløv, H 2022, ' Pre-transplantation vitamin E levels and acute graft-versus-host disease after non-myeloablative allogeneic hematopoietic cell transplantation ', Transplant Immunology, vol. 74, 101650 . https://doi.org/10.1016/j.trim.2022.101650
Background: Low pre-transplantation plasma vitamin E levels have been associated with increased risk of acute graft-versus-host disease (GvHD) after myeloablative allogeneic hematopoietic cell transplantation (allo-HCT). We aimed to investigate the a
Autor:
Ove Juul Nielsen, Lars Klingen Gjærde, Lone Smidstrup Friis, Lasse Hjort Jakobsen, Søren Lykke Petersen, Brian Kornblit, Nina Toft, Gitte Olesen, Ida Schjødt, Hanne Vibeke Marquart, Mette K. Andersen, Cecilie Utke Rank, Niels Smedegaard Andersen, Henrik Sengeløv
Publikováno v:
Gjærde, L K, Rank, C U, Andersen, M K, Jakobsen, L H, Sengeløv, H, Olesen, G, Kornblit, B, Marquart, H, Friis, L S, Petersen, S L, Andersen, N S, Nielsen, O J, Toft, N & Schjødt, I 2022, ' Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults : a Danish population-based study ', Leukemia and Lymphoma, vol. 63, no. 2, pp. 416-425 . https://doi.org/10.1080/10428194.2021.1992620
We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000–2019. Patients had a median (min–max) age of 36 (18–74) years at HCT and were followed for a median of eigh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3fe5ef2018cc45ffbf9c812e9861729
https://vbn.aau.dk/da/publications/8be4b8c3-f62e-4927-9e73-0e30af1b9381
https://vbn.aau.dk/da/publications/8be4b8c3-f62e-4927-9e73-0e30af1b9381